First-Line Therapy for Advanced RCC: Optimizing Adverse Event Management

Video

A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.

Transcript:

Moshe Ornstein, MD: The problem is all these IO [immuno-oncology]-based regimens have some toxicities associated with them. How do you generally approach this when a patient comes in with some toxicity, whether it’s from [ipilimumab and nivolumab] or one of the IO/TKIs [tyrosine kinase inhibitors]?

Ulka N. Vaishampayan, MBBS: For the immune checkpoint toxicities, if it’s just an IO/IO regimen, you anticipate some of the immune-related adverse events. The most common ones with [ipilimumab and nivolumab] are colitis and pneumonitis. Thyroid dysfunction can happen in all patients who are treated, whether with [a vascular endothelial growth factor] TKI or [an] IO. That is something you must monitor.

The biggest things I find in toxicity management tends to be: anticipate and educate. You must educate patients and their caregivers that even things that seem like a flu, an average infection, or fatigue may actually be adrenal insufficiency. For them to bring it to our attention sooner [is] better, so we can address it accordingly. That can save a whole lot of time and worsening of the toxicities.

The other thing is if there are suspected immune-related adverse events, [then we would] start immunosuppression [sooner], first with steroids and then move on to other immunosuppressive agents, such as infliximab or mycophenolate, if they’re not responding to steroids. The timing is fairly critical. You don’t wait weeks and weeks, [and] you don’t try to rule out every infection and try to do colonoscopies on these patients. Clinically, if they’re not improving on steroid immunosuppression, it’s time to move on and consider other heavy-duty immunosuppression. What do you think?

Moshe Ornstein, MD: I completely agree. I like how you phrase that in terms of being aware, anticipating, and educating. I tell patients and their families that no matter what [they’re] starting on day 1 [of their] first treatment, that’s the baseline, and [to] call with any changes. We have [staff] available 24/7. It’s really important. The time to start steroids is as soon as the word steroids comes to mind. You can always start it for a short period of time, then stop. But if you think a patient needs steroids, it’s critical. With IO/IO, it’s easier because you know the toxicity is immune driven. But with IO/TKI, sometimes for things like diarrhea or elevated [liver function tests], you must tease it out. It’s straightforward to hold a TKI for a few days and see [whether] things get better. If not, you move on to steroids. I like the idea of starting to educate the community about moving beyond steroids, and to know not [only] that we must give steroids—and we’ve known that now for 10 years—but [also] at what point are we moving beyond steroids? That’s the next level of education that we must share with oncologists and some of the subspecialists.

Transcript edited for clarity.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content